Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone.

Objective: At our institution, patients with hematological disease who require pneumonia (PJP) prophylaxis were administered atovaquone at a low dose (750 mg/day). However, there have been few reports on the efficacy of low-dose atovaquone administration, and the purpose of this study is, therefore, to investigate its effectiveness.

Materials And Methods: We investigated the expression of PJP in patients with hematological disease who received atovaquone administration.